A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension

Launched by ZHEJIANG UNIVERSITY · Jul 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment approach for people with a serious condition called acute necrotizing pancreatitis, which is a severe inflammation of the pancreas that causes tissue damage. Some patients with this condition also develop a complication called pancreatic sinistral portal hypertension, where increased pressure affects certain veins near the pancreas. The study is looking at whether removing the spleen (a surgery called splenectomy) during the cleaning out of damaged pancreatic tissue (called debridement) can improve recovery and outcomes for these patients.

If you are between 18 and 75 years old, have this specific type of pancreatitis with the vein pressure problem, and need open surgery to remove infected pancreatic tissue, you might be eligible to join. Participants will undergo the usual surgery to clear the damaged tissue, and some will have their spleen removed as part of the treatment. The study will then compare how well patients recover and do over time with or without spleen removal. It’s important to note that patients with other serious health problems before their pancreatitis or those having less invasive surgeries won’t be eligible. This trial is currently recruiting participants and aims to find better ways to help people with this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age between 18 and 75 years.
• • 2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension.
• • 3. Patients undergoing open debridement for infected pancreatic necrosis
• Exclusion Criteria:
• • 1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP).
• • 2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP.
• • 3. Patients with pre-existing hematological diseases prior to AP.
• • 4. Patients undergoing laparoscopic or nephroscopic debridement.